January 2017

CancerGene Connect Taps Seasoned Executive John Oberg as Vice President of Sales and Marketing

Tue, 31/01/2017 - 09:53
Dallas, USA, 29th January 2017 / Sciad Newswire / CancerGene Connect, a wholly owned Subsidiary of OMMDOM, Inc.,

Cypralis granted new Innovate UK early stage award to develop cyclophilin D inhibitors targeting degenerative diseases

Mon, 23/01/2017 - 07:30
Cambridge, UK, 23rd January 2017 / Sciad Newswire / Cypralis, a life sciences company focused on the discovery of therapeut

Biotech and Money London adds Medtech and Money Day

Wed, 18/01/2017 - 10:00
Biotech and Money London 2017, a C-level executive conference that helps build linkages and business opportunities for UK and European life science companies taking place on 7-8 February 2017, has added a Medtech and Money Day to help medtech executives, investors and pharma access high-value collaboration opportunities.

ECI Partners Private Equity Investment in SAP Consultancy Edenhouse Solutions

Fri, 13/01/2017 - 13:00
Birmingham, UK, 13th January 2017 / Sciad Newswire / Edenhouse Solutions, a Birmingham based SAP consultancy, ha

Will Plant and Algae-Based Protein Consumption Overtake Animal-Based Foods?

Thu, 12/01/2017 - 10:00
San Francisco, UK, 12th January 2017 / Sciad Newswire / With the world’s population projected to hit 9.9 billion by 2050, experts are continuing to look for susta

Synpromics announces a research collaboration with GE Healthcare to Extend the Toolbox for Production of Biologics

Wed, 04/01/2017 - 07:30
Edinburgh, UK, 4th January 2017 / Sciad Newswire / Synpromics Ltd, the leading synthetic promoter and gene control compan

Prokarium and Probiomed in UK-Mexico Collaboration to Scale-Up Manufacture of Thermostable Vaccines with a Focus on Diarrhoea

Wed, 04/01/2017 - 07:00
Prokarium and Probiomed today announced the start of their collaboration to scale-up the manufacture of orally administered vaccines in a formulation that would enable stability at 40°C for several weeks. The first vaccine to be manufactured will be developed to prevent so-called ‘Montezuma’s revenge’ or diarrhoea, which affects the local population as well travellers in Mexico and many countries.